Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer.

Trial Profile

Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Bleomycin; Cisplatin; Etoposide
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2014 Data cleaning project 4: Deleted descriptor - Filgrastim (concomitant medicaton).
    • 23 Jan 2012 Results published in the Journal of Clinical Oncology.
    • 22 Jun 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top